Rituximab for relapsing or refractory lupus nephritis: complete response in about four in ten

Design

Systematic review and meta-analysis of single-arm studies

Population

445 patients with relapsing or refractory lupus nephritis in 19 studies

Primary outcome

Complete, partial and overall renal response

Effect

CRR 41% (95% CI 28–54%) at 12 months; ORR about 70%

A systematic review and meta-analysis pooled 19 studies of 445 patients given rituximab-based rescue or add-on therapy for relapsing or refractory lupus nephritis.

Complete renal response was 33% at 6 months, 41% at 12 months and 42% at 24 months; overall response (complete or partial) was about two-thirds throughout. Proteinuria fell by about 2.7 g/day and creatinine by about 12 µmol/L.

There was no comparison group, so these figures describe outcomes in treated patients rather than a benefit over alternatives. Rituximab is often used in this setting in India, where newer agents may be unaffordable, and these pooled rates help set expectations.

• In relapsing or refractory lupus nephritis, expect complete renal response in roughly 40% at a year with rituximab-based therapy.
• Confirm adherence and repeat biopsy where activity versus chronicity is uncertain before escalating.
• Screen for hepatitis B before rituximab.
• Monitor immunoglobulins and infection risk with repeated courses.

Why it matters

It gives numbers for a decision usually made on anecdote.

Don't overread it

Without comparison groups, these response rates cannot show rituximab works better than other rescue options.

The statistics, in plain English

Pooled proportions describe how often patients responded across studies; wide intervals (for example 0.26–0.60 at 24 months) reflect small and varied studies.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.